Correspondence

Further advice on scheduling of cannabis-derived medicinal products

Further advice from the Advisory Council on the Misuse of Drugs (ACMD) to the Home Office about the scheduling of cannabis-derived medicinal products.

• From: Advisory Council on the Misuse of Drugs
• Published: 11 September 2018

Documents

ACMD response letter on cannabis-derived medicinal products

PDF, 489 KB, 9 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

Letter from the ACMD chair, Dr Owen Bowden-Jones, to the Home Secretary Sajid Javid and Secretary of State for Health and Social Care Matt Hancock, responding to the consultation on a proposed definition of cannabis-derived medicinal products.

This follows the ACMD’s initial short-term advice recommending products meeting this definition are moved out of the requirements of schedule 1.

Published 11 September 2018